Cologne, September 1st, 2020
PAIA introduces its new Glycan Screening Services business
PAIA Biotech officially launches its new Glycan Screening Services business starting from September 2020.
This new offering is the first glycan screening service which is truly adapted to the needs of customers in the CLD and Upstream development departments.
It allows our customers to screen up to hundreds of supernatant samples in less than two weeks and obtain product quality related data at an early stage.
“With this new service we provide our customers with an easy access to our glycan screening technology and our experienced team here at PAIA Biotech” says PAIA´s CEO Sebastian Giehring,“ we have seen growing interest in these kinds of services in the past year and are happy to making this an official product now.”
PAIA´s glycan screening services are based on the patented PAIA technology and follow standardized workflows that utilize PAIA´s glycan screening assays. These customizable assay kits continue to be marketed as consumables by PAIA Biotech.
Cologne, July 1st, 2020
PAIA receives Eurostars grant for TIPQmed project
PAIA Biotech is pleased to announce that the project “Targeted Improvement of Therapeutic Protein Quality Through Cell Culture Media” (TIPQMed) project was granted a total of about € 1,8 Mio. Euro through the Eurostars program over the next 30 months.
The goal is to identify cell culture media compositions that allow precise modulation of product quality attributes and use high throughout technologies to systematically test a multitude of conditions. The international TIPQMed consortium is led by Florabio Teknololoji (Turkey) and comprises technology providers PAIA Biotech (Germany), GlycoMScan (Netherlands) and Biberach University of Applied Sciences (Germany).
"The influence of culture media on protein glycosylation has been a mystery over decades.We will finally go into the absolute details to understand the dependencies and develop novel culture media", says Aziz Cayli, CEO of Florabio. “We believe that TIPQMed has a good chance for success because of the complementing expertise and willingness to succeed for all of the project members."
PAIA´s CEO Sebastian Giehring commented: ”We are excited to demonstrate our ability to screen product quality in cell line and bioprocess development in such a comprehensive project and refine our assay technology together with our partners."
Monique Scherpenzeel, CEO of GlycoMScan added:“We are very happy to have here the right capabilities and collaborations to precisely monitor the influence of cell culture conditions on therapeutic antibody glycosylation, which is the fulfillment of my long-standing wish to contribute to optimal treatment efficacy through understanding the process of glycosylation.”
For Hans Kiefer, one of the collaborators at Biberach University of Applied Sciences, this project "is an excellent opportunity to use and extend our capabilities in automated protein analysis and chemometric modelling in a real-life setting, where the path to market is short."
Eurostars supports international innovative projects led by research and development- performing small- and medium-sized enterprises (R&D-performing SMEs). With its bottom-up approach, Eurostars supports the development of rapidly marketable innovative products, processes and services that help improve the daily lives of people around the world. Eurostars is a joint program between EUREKA and the European Commission, co-funded from the national budgets of 36 Eurostars Participating States and Partner Countries and by the European Union through Horizon 2020.